The emergence of scientific disciplines, as well as the policies aimed to steer them, have geographical implications. This becomes visible in areas such as genomics and related fields. In this paper, the relation between scientific evolution, political decisions and geographical configuration is studied. The recent formation of bioinformatics in Brazil is focused on. The study involves an analysis of data collected on the website of CNPq, a funding agency attached to the Ministry of Science and Technology. Furthermore, I conducted fieldwork in four cities, interviewing 15 bioinformaticians. In the history of Brazilian bioinformatics, three periods can be identified. In the first period (1900-1996), bioinformatics was actually absent, but biology research groups were formed which would subsequently explore bioinformatics. The second period (1997-2006) was marked by the emergence of the discipline and geographical concentration of major research groups in the southern part of Brazil. A third period can be pointed to (2007-2014), in which political choices have turned geographical diffusion and institutional equality into a national target. As a consequence of the recent shifts, genomics and bioinformatics researchers have been involved in a debate, some defending the existence of few specialized research and sequencing platforms, whereas others welcoming the constitution of a scientific scenario based on decentralized platforms. I defend an intermediate solution, whereby some places would be selected to be genomics hubs. This would fit the regional diversity of this vast country, in addition to tackling the scientific weaknesses of the northern area.

Keywords:
Bioinformatics, Brazil, Decision-making, Genomics, Spatial inequalities
1.
Santos M: La nature de l'espace: technique et temps, raison et émotion. Paris, L'Harmattan, 2000.
2.
Salter B, Faulkner A: State strategies of governance in biomedical innovation: aligning conceptual approaches for understanding ‘Rising Powers' in the global context. Global Health 2011;7:1-14.
3.
Bicudo E: ‘Geographical randomization' and ‘social exploitation' in clinical research: world trials in Santiago, Chile. Health Place 2011;17:807-813.
4.
Chow M, Fernandez D: Intellectual property strategy in bioinformatics. J Intellect Property Rights 2003,8:130-137.
5.
Gopalan R: Bioinformatics: scope of intellectual property protection. J Intellect Property Rights 2009;14:46-51.
6.
Suárez-Díaz E: Making room for new faces: evolution, genomics and the growth of bioinformatics. Hist Philos Life Sci 2010,32:65-89.
7.
Araújo ND, Farias RP, Pereira PB, Figueirêdo FM, Morais AMB, Saldanha LC, et al: A era da bioinformática: seu potencial e suas implicações para as ciências da saúde. Estudos Biol 2008,30:143-148.
8.
Howard K: The bioinformatics gold rush. Sci Am 2000,287:58-63.
9.
Ouzonis CA, Valencia A: Early bioinformatics: the birth of a discipline - a personal view. Bioinformatics 2003;19:2176-2190.
10.
Conselho de Informações sobre Biotecnologia: Bioinformática sai das academias científicas e vai para os laboratórios. Biotech 2004;7:1-4.
11.
Edmonds A: ‘‘Almost invisible scars'': medical tourism to Brazil. Signs 2011;36:297-302.
12.
Edmonds A: Learning to love yourself: esthetics, health, and therapeutics in Brazilian plastic surgery. Ethnos 2009;74:465-489.
13.
Petryna A: When Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Oxford, Princeton University Press, 2009.
14.
Bicudo E: Pharmaceutical Research, Democracy and Conspiracy: International Clinical Trials in Local Medical Institutions. London, Gower/Ashgate, 2014.
15.
Chang J, Zhu X: Bioinformatics databases: intellectual property protection strategy. J Intellect Property Rights 2010,15:447-454.
16.
Hagen JB: The origins of bioinformatics. Nat Rev Genet 2000;1:231-236.
17.
Bicudo E: Produção de medicamentos e território brasileiro: por uma concepção horizontal do desenvolvimento; in Viana A, Ibañes N, Elias P (eds): Território, saúde e desenvolvimento. São Paulo, Hucitec, 2009, pp 151-190.
18.
Palmério J: O custo dos remédios e a economia médico-farmacêutica. São Paulo, 1942.
19.
Lewis J, Bartlett A: Inscribing a discipline: tensions in the field of bioinformatics. New Genet Soc 2013;32:243-263.
20.
ComCiência: Concentração da bioinformática decorre do Genoma. 2003. http://www.comciencia.br/reportagens/bioinformatica/bio07.
21.
Dal Poz MES: Da dupla hélice à tripla hélice: o projeto genoma xylella. Campinas, University of Campinas (Unicamp), 2000.
22.
Simpson AJG, Perez JF: ONSA, the São Paulo virtual genomics institute. Nat Biotechnol 1998;16:795-796.
23.
Harvey M, McMeekin A: Brazilian genomics and bioinformatics: instituting new innovation pathways in a global context. Econ Soc 2005;34:634-658.
24.
Bongiolo E: Análise panorâmica da bioinformática no Brasil: propostas da gestão de pessoas para os laboratórios de pesquisa. Criciúma, Universidade do Extremo Sul Catarinense (Unesc), 2006.
25.
Dias EL: Redes de pesquisa em genômica no Brasil: políticas públicas e estratégias privadas frente a programas de sequenciamento genético. Campinas, University of Campinas (Unicamp), 2006.
26.
Marques ACH, Cepêda VA: Um perfil sobre a expansão do ensino superior recente no Brasil: aspectos democráticos e inclusivos. Perspectivas 2012;42:161-192.
27.
Mackenzie A: Bringing sequences to life: how bioinformatics corporealizes sequence data. New Genet Soc 2003;22:315-332.
28.
Stein LD: The case for cloud computing in genome informatics. Genome Biol 2010;11:1-7.
29.
Jaeger PT, Lin J, Grimes JM, Simmons SM: Where is the cloud? Geography, economics, environment, and jurisdiction in cloud computing. First Monday 2009;14.
30.
Schatz MC, Langmead B, Salzberg SL: Cloud computing and the DNA data race. Nat Biotechnol 2015;28:691-693.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.